Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
KELNOR 1 / 35 SUMMARY
Kelnorô 1/35 (28 Day Regimen)
(ethynodiol diacetate and ethinyl
estradiol tablets, USP)
Kelnorô 1/35 (28 Day Regimen) (ethynodiol diacetate and ethinyl estradiol tablets, USP): Each light yellow tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol.
Kelnorô 1/35 (28 Day Regimen) (ethynodiol diacetate and ethinyl estradiol tablets, USP) are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Media Articles Related to Kelnor 1 / 35 (Ethynodiol / Estradiol)
Trump Signs Resolution for States to Block Family Planning Funds
Source: Medscape Medical News Headlines [2017.04.14]
President Donald Trump on Thursday signed a resolution that will allow U.S. states to restrict how federal funds for contraception and reproductive health are spent, a move cheered by anti-abortion campaigners.
Reuters Health Information
Published Studies Related to Kelnor 1 / 35 (Ethynodiol / Estradiol)
Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. [1979.02]
PIP: Bioavailability and pharmacokinetics of norethisterone (NE) were studied in 12 women, aged 21-37 years, after oral doses of ethynodiol diacetate (EDA). Plasma NE levels, measured by radioimmunoassay, were used to compare the bioavailability of EDA tablets (Ovulen 50; 1 mg EDA plus .05 mg ethinyl estradiol) with that of a standard oral solution of EDA...
Efficacy and safety of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms, with an emphasis on contraceptive efficacy. A phase IV trial. [1991.04]
A phase IV trial evaluated the efficacy and safety of a monophasic oral contraceptive formulation, ethynodiol diacetate, 1 mg, plus ethinyl estradiol, 35 micrograms (EDA 1 mg with EE 35 micrograms) (Demulen 1/35). Nine hundred eighty-three community-based obstetrician-gynecologists treated a total of 7,759 patients with EDA 1 mg with EE 35 micrograms for one to eight months...
Complexion changes in oral contraceptive users. Results from a phase IV multicenter trial evaluating the safety and efficacy of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms. [1991.04]
An open-label, phase IV, multicenter survey of obstetrician-gynecologists was conducted to evaluate the efficacy and safety of a low-dose monophasic oral contraceptive, ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms. Surveys from 983 community-based physicians reported on 6,382 women...
Serum and placenta levels of ethynylestradiol in presence of ethynodiol diacetate after oral administration. [1982.07]
PIP: The ethinyl estradiol concentration--in the presence of ethynodiol diacetate--in serum following oral administration was measured by a rapid radioimmunoassay method developed by the authors. It was found that the peak level was reached 1 hour after administration, and even after 12 hours, a significant amount of free ethinyl estradiol was present in the serum...
Page last updated: 2017-04-14